期刊文献+

2例非小细胞肺癌患者的个体化药学服务 被引量:1

Personalized Pharmaceutical Service for 2 Cases of Non-small Cell Lung Cancer Patients
下载PDF
导出
摘要 目的:为非小细胞肺癌(NSCLC)患者提供个体化药学服务。方法:对2例NSCLC患者进行治疗方案评估、用药监护、基因监测。结果:NSCLC患者进行基因检测后再服用埃克替尼近期效果好。结论:对NSCLC患者进行个体化治疗具有较好的近期疗效及安全性,耐受性良好。 Objective: To provide personalized pharmaceutical service for non-small cell lung cancer (NSCLC) patients. Methods : Personalized pharmaceutical service was carried out for two NSCLC patients, including the assessment of therapy regimen, medication monitoring and genetie monitoring. Results: The recent effect in the patients was improved with genetic monitoring before the administration of ieotinib. Conclusion: Personalized chemotherapy has better efficacy, safety and toleration for NSCLC patients during the administration of icotinib.
出处 《中国药师》 CAS 2015年第7期1183-1184,1202,共3页 China Pharmacist
关键词 临床药师 药学服务 非小细胞肺癌 个体化 Clinical pharmacist Pharmaceutical service Non-small cell lung cancer, Personalization
  • 相关文献

参考文献19

  • 1.lemal A, Siegel R, Xu J, et al. Cancer statistics, 2010 [ J ]. CA Cancer J Glin ,2010 , 60 : 277-300.
  • 2Pugh TJ , Bebb G, Barclay L. Correlations of EGFR mutations and in- creases in EGFR and HER2 copy number to gefitinib response in a retrospective analysis of lung cancer patients [ J ]. Cancer, 2007, 7 : 128.
  • 3Zhang WP, Stabile LP, Keohavong P, et al. Mutation and Polymor- phism in the EGFR-TK Domain Associated with Lung Cancer [ J ]. J Thorac Oncol,2006,1 (7) : 635-747.
  • 4Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005[J]. CA Cancer J Clin,2006 ,55 :10-30.
  • 5Li CG, Sun YH, Fang ZY, et al. Comprehensive Analysis of Epider- mal Growth Factor Receptor Gene Status in Lung Adenocarcinoma [J]. J Thorac Oncol. 2011.6.. 1016-1021.
  • 6Marchetti A, Martella C, Felicioni L, et al. EGFR small cell lung cancer: analysis of a large series of cases and develop- ment of a rapid and sensitive method for diagnostic screening with po- tential implications on pharmacologic treatment [ J ] . J Clin Oncol , 2005,23(4) : 857- 866.
  • 7Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological fea- tures associated with epidermal growth factor receptor gene mutations in lung cancers[J]. J Natl Cancer lnst ,2005 ,97 ( 5 ) :339-346.
  • 8Paez JG, Jame PA, Lee JC, et al. EGFR mutations in luing cancer: cor- relation with clinical response to gefitinib therapy [ J ]. Science, 2004, 304 ( 5676 ) : 1497-1500.
  • 9Lynch TJ, Bell DW, Sondella R, et al. Activating mutations in the epidermal growth factor receptor underlying reponsivenes of non-small- cell lung cancer to gefitinib [ J ]. N Engl J Med, 2004,350 ( 21 ) : 2129-2139.
  • 10Sreenath VS, Daphne WB, Settleman JH, et al. Epidermal growth factor receptor mutations in lung cancer[ J] . Nature, 2007, 7 ( 3 ) : 169- 183.

二级参考文献40

  • 1邬楠,王爱平,王印祥.表皮生长因子受体酪氨酸激酶抑制剂BPI-2009的抗肿瘤作用及其机制的研究[J].中国临床药理学与治疗学,2005,10(4):456-461. 被引量:7
  • 2吴健虹,谢秋玲,陈小佳,洪岸.表皮生长因子受体EGFR及其信号传导[J].生命科学,2006,18(2):116-122. 被引量:40
  • 3Tsao MS, Sakurada A, Cutz JC,et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome[J]. N EnglJ Med,2005,353(2):133--146.
  • 4Taron M, Ichinose Y, Rosell R, et al. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptorareassociatedwith improved survival in gefitinib-treated chemorefraetory lung adenocarcinomas[J]. Clin Cancer Res,2005,11 (16) :5878--5886.
  • 5Shigematsu H, Li L, Takao T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers[J]. J Natl Cancer I, 2005, 97(5) :339--347.
  • 6Kosaka T, Yatabe Y, Endoh Y,et al. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications[J]. Cancer Res, 2004,64(24) :8919- 8923.
  • 7Paez JG, Pasi AJ, Lee JC,et al. EGFR mutations in lung cancer:correlation with clinical response to gefitinib therapy[J]. Science, 2004,304(5676) : 1497 --1450.
  • 8Sreenath VS, Daphne WB, Settleman JH, et al. Epidermal growth factor receptor mutations in lung cancer[J]. Nature, 2007,7(3): 169-- 183.
  • 9Blackledge G, Verbuch S. Gefitinib ( Iressa , ZD1839) and new epidermal growth {actor receptor inhibitors[J]. Brit J Cancer, 2004, 90(3):566-- 572.
  • 10Cappuzzo F, Finocchiaro G, Metro G, et al. Clinical experience with gefitinib: An update[J]. Hematology,2006 ,58(1):31--45.

共引文献7

同被引文献5

引证文献1

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部